A randomized, double blind, comparative study of vitamin D3 versus placebo in infant with atopy to prevent developing to asthma

A randomized, double blind, comparative study of vitamin D3 versus placebo in infant with atopy to prevent developing to asthma - ATP XI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004159

Enrollment

500

Registered

2010-10-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic infants with IgE RAST + and more

Interventions

vitamin D3 supplement placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 0 &#8211; 3 years old IgE RIST positive (at least one item +) or eosinophil fraction 5% and more Frequency of wheezing bronchitis is two and less in the past history Infant who has not been diagnosed as bronchial asthma In case of infant less than 1 year old, infant who is taking breast feeding dominantly. Obtained informed consent

Exclusion criteria

Exclusion criteria: 1. Already taking vitamin D supplement or 1,25 vitamin D 2. History of wheezy bronchitis 3 times and more, incubation and respiratory support during newborn period, addmitted due to RSV infection, urinary stone. 3. chronic disease including fracture, mental retardation, difficulty in swallowing.

Design outcomes

Primary

Measure	Time frame
asthma diagnosed by collaborating medical doctors	—

Secondary

Measure	Time frame
Improvement of IgE RIST, RAST, SCORAD, reduce of drug usage	—

Countries

Japan

Contacts

Public ContactMitsuyoshi Urashima

Jikei University School of Medicine Molecular Epidemiology

03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026